Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
fluzopanib + bevacizumab
- Development stage
- Unknown
- Lead developer
- Hengrui Therapeutics
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Oral, Intravenous
01
Overview
Fluzopanib + bevacizumab is a combination therapy consisting of fluzopanib, a small molecule tyrosine kinase inhibitor, and bevacizumab, a monoclonal antibody targeting vascular endothelial growth factor A (VEGF-A). This combination is designed to provide dual inhibition of angiogenesis pathways in cancer treatment. Fluzopanib inhibits multiple receptor tyrosine kinases involved in tumor angiogenesis and proliferation, while bevacizumab binds VEGF-A to prevent its interaction with receptors on the surface of endothelial cells, thereby inhibiting new blood vessel formation essential for tumor growth. The combination aims to enhance anti-tumor efficacy by blocking complementary mechanisms within the angiogenic pathway.
- Other names
- fluzopanib and bevacizumab
02
Targets
FGFR (Fibroblast growth factor receptor)PDGFRA (Platelet-derived growth factor receptor alpha)PDGFRB (Platelet-derived growth factor receptor beta)VEGFA (Vascular endothelial growth factor A)VEGFR-1 (Vascular endothelial growth factor receptor 1)VEGFR2 (Vascular endothelial growth factor receptor 2)VEGFR4 (Vascular endothelial growth factor Receptor-3)KIT (c-KIT proto-oncogene receptor tyrosine kinase)
Beyond the preview
Go deeper on fluzopanib + bevacizumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on fluzopanib + bevacizumab.